Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMB 305

Next Previous
Drug Profile

CMB 305

Alternative Names: CMB-305; G-305/LV-305; ID-CMB305; ID-G305/ID-LV305; ID-LV305/ID-G305; LV-305/G-305

Latest Information Update: 28 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Design
  • Developer Genentech; Immune Design
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides; RNA vaccines; Synthetic vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes - Sarcoma

Highest Development Phases

  • Phase III Synovial sarcoma
  • Phase II Soft tissue sarcoma
  • No development reported Liposarcoma; Solid tumours

Most Recent Events

  • 28 Oct 2021 No recent reports of development identified for phase-I development in Liposarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
  • 28 Oct 2021 No recent reports of development identified for phase-I development in Synovial-sarcoma(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)
  • 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Locally recurrent, Metastatic disease, Monotherapy, In adults) in USA (Parenteral, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top